Марина Майстренко

Mrs. Марина Майстренко

Department of Management and Economics of Pharmacy, Ryazan State Medical University named after Academician I.P. Pavlov, Ryazan, Ryazanskaya Oblast’, Russia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2023 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Open access
PDF file
МММарина Майстренко
Марина Майстренко
EYE. N. Yakusheva
E. N. Yakusheva
DTD. S. Titov
D. S. Titov
Antibiotic resistance is a global health problem. Its solution requires concerted efforts on the scale of global cooperation. Programs to prevent the development of antibiotic resistance, as well as to stimulate the development of new drugs with antimicrobial activity are implemented in a lot of countries. The use of antibacterial drugs, including inappropriate use, has increased during the COVID-19 pandemic, which may contribute to the growth of antibiotic resistance. The aim of this study is to assess the measures aimed at combating the growing antibiotic resistance in the world, analyze the market of antimicrobial drugs in the Russian Federation, as well as collect and process information on the antibiotic resistance of microorganisms that cause infectious diseases that develop against the backdrop of COVID-19. The analysis of the state register of the Russian Federation for antibacterial drugs was carried out. Mathematical and statistical processing of antibiotic resistance was performed according to the data of the European Surveillance Atlas of Infectious Diseases for Klebsiella pneumonia in relation to fluoroquinolones, aminoglycosides, third-generation cephalosporins, as well as combined resistance to these antibacterial drugs over the past sixteen years.

Verified
Journal Article
Open access
PDF file
ONOksana Nemyatykh
Oksana Nemyatykh
МММарина Майстренко
Марина Майстренко
DDDina D. Demchenko
Dina D. Demchenko
INIgor A. Narkevich
Igor A. Narkevich
SOSergey Okovityi
Sergey Okovityi
VTViladimir Timchenko
Viladimir Timchenko
The purpose of this review was to conduct a comparative assessment of the concepts of therapy for pediatric patients with COVID-19 in the framework of global clinical practice. A structural analysis of the range of drugs and treatment strategies in the context of etiotropic, pathogenetic, and symptomatic therapy has shown that in the global context and in real clinical practice, the etiotropic-pathogenetic approach based on information about the effectiveness of individual medical technologies prevails today. It has been established that eight international nonproprietary/grouping names are present in international practice as means of etiotropic therapy for pediatric patients with COVID-19, and 18 positions are used for pathogenetic therapy. In terms of frequency of occurrence, the leading positions are occupied by remdesivir and the combination of nirmatrelvir with ritonavir, as well as dexamethasone and tocilizumab. The paper emphasizes the relevance of research in the field of evaluating the effectiveness of individual treatment regimens as well as the analysis of the delayed consequences of pathology suffered in childhood under the conditions of using various approaches to pharmacotherapy.

30 December 2023 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
EKE. P. Kulikov
E. P. Kulikov
MSM. V. Shomova
M. V. Shomova
DTD. S. Titov
D. S. Titov
ADA. N. Demko
A. N. Demko
МММарина Майстренко
Марина Майстренко
Background. Sentinel lymph node (SLN) biopsy is a reliable diagnostic method used to assess the spread of the malignant process in regional lymph nodes. Currently, this method is of great importance in treatment planning for early breast cancer and allows to avoid immediate and long-term complications of lymph node dissection. SLN detection can be performed using the radionuclide method, the disadvantages of which are associated with the peculiarities of working with radiopharmaceuticals and additional costs when using them. An alternative method is fluorescence lymphography (FL) with indocyanine green.Objective: performing a pharmacoeconomical study (cost-effectiveness analysis) comparing the cost-effectiveness of methods for detecting SLN in breast cancer: radionuclide diagnosis (RD) using a radiopharmaceutical based on sodium pertechnetate [99mТс] and FL using indocyanine green (Life Sciences OCPK LLC, Russia) and "IC GOR System" device (Central Design Bureau of Information and Control Systems JSC, Russia).Material and methods. The values of the cost-effectiveness ratio (CER) were calculated and compared for the two indicated methods of detecting SLN in breast cancer. Information on the RD method clinical efficacy was taken from the published data. SLN detection by the FL method with the use of indocyanine green and domestic apparatus was performed on the basis of the Regional Clinical Oncology Dispensary (Ryazan) in 53 patients with breast cancer. To assess the reliability of the obtained results a deterministic multivariate sensitivity analysis was performed.Results. The obtained CERFL values were significantly lower than the median CERRD values by average of 43.29% (p<0.001): from 40.36% (p<0.001) to 44.96% (p<0.001). The geometric mean CERFL was lower than CERRD by 39,40% (from 37.99% to 42.80%), and their 95% confidence intervals (CI) did not intersect. Deterministic multivariate sensitivity analysis demonstrated robustness of the obtained data to the transformation of RD cost parameters. Nevertheless the geometric mean and its 95% CI of CERRD and CERFL did not intersect under any circumstances.Conclusion. According to the results of a pharmacoeconomic study, it is more economically profitable to detect SLN in breast cancer using indocyanine green and a domestic device for FL, as its costs per unit of efficiency were 38–45% lower than for RD using a radiopharmaceutical based on sodium pertechnetate [99mТс].

7 October 2022 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Closed access
PDF file
DTDmitriy S. Titov
Dmitriy S. Titov
EYElena N. Yakusheva
Elena N. Yakusheva
YNYuliya E. Novikova
Yuliya E. Novikova
МММарина Майстренко
Марина Майстренко
EUEkaterina E. Uliteonok
Ekaterina E. Uliteonok
INTRODUCTION: The regulatory and legal framework controlling the procedure for registration and circulation of prescriptions in the Russian Federation is dynamic and changes with the level of development of digital technologies. The Ministry of Health of the Russian Federation is continuously working on improvement of the existing regulatory documents with the aim to optimize the activities of medical and pharmaceutical workers in the field of issuing prescriptions and sale of prescription drugs. The article presents an analysis of the regulatory and legal framework regulating the procedure for registration and circulation of prescriptions for medical drugs. CONCLUSIONS: On March 1, 2022, Order No. 1094n came into force, that regulates the new procedure for registration and circulation of prescriptions. The changes made to the rules are aimed at optimizing the procedure for issuing prescriptions and simplifying it for doctors. However, for a number of formulations used in the current version of the order, explanations from the Ministry of Health of the Russian Federation are desirable, or it is necessary to form a unified opinion of the professional community.

31 March 2022 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Closed access
PDF file
DTDmitriy S. Titov
Dmitriy S. Titov
SPSergey K. Pravkin
Sergey K. Pravkin
ANAleksandr A. Nikiforov
Aleksandr A. Nikiforov
ESElena S. Savost’yAnova
Elena S. Savost’yAnova
МММарина Майстренко
Марина Майстренко
INTRODUCTION: Vildagliptin is one of the drugs of choice in the treatment of type 2 diabetes mellitus (DM). In the literature review, no study has reported the effect of vildagliptin on the expression level of the transporter protein P-glycoprotein (P-gp, ABCB1 protein). AIM: To assess the in vivo effects of vildagliptin on the level of Р-gp expression in normal conditions and experimental alloxan-induced type 2 DM. MATERIALS AND METHODS: Type 2 DM was induced by a single intravenous injection of freshly prepared alloxan monohydrate solution in citrate buffer (pH = 4.0) at a dose of 80 mg/kg. Glucose content (mmol/L) was determined by the glucose oxidase method using Human kit (Germany) and insulin content (U/mL) by radioimmunoassay technique using Immunotech kit (Czech Republic). As an express method for the determination of glucose levels in the whole blood, OneTouch UltraEasy electrochemical glucose monitor (USA) was used. The level of P-gp expression in rabbit tissues (i.e., jejunum, liver, kidney, and cerebral cortex) was evaluated by the indirect histochemical method. After preliminary treatment, the histological material was embedded in paraffin. Antigens were retrieved before the immune-staining reaction. Then, the sections were incubated with primary antibodies to P-gp (ABCB1 antibody, middle region; 0.1 mL [Aviva Systems Biology ARP51326-P050, USА]). For immune staining, a polymer detection system with a peroxidase label (Leica Microsystems, Germany) was used. The cell nuclei were stained with hematoxylin. Photos of the micropreparation were captured using Canon Power Shot G5 digital camera with 400 magnification. Digital images were analyzed and processed using ImageJ and IHC Profiler plugin designed for quantitative immunohistochemical analysis. The results obtained from healthy animals, animals with alloxan-induced DM, healthy animals administered vildagliptin, and animals with modeled DM administered vildagliptin were compared. RESULTS: After day 14 of administration to healthy rabbits and day 5 of vildagliptin discontinuation (5 mg/kg), no statistically significant changes in P-gp expression in the aforementioned tissues and the levels of basal and postprandial insulin and blood glucose were noted. After the 14-day therapy of alloxan-induced type 2 DM with vildagliptin (5 mg/kg), a statistically significant recovery of expression of the P-gp expression in the jejunum, liver, and kidney was reduced due to the underlying pathology. In addition, the values of healthy rabbits and statistically significant normalization of the insulin and blood glucose levels were observed. On day 5 of drug cancellation, significant inhibition of P-gp expression in the jejunum, liver, and kidney was noted again, and there was a significant reduction of postprandial insulin and blood glucose. No significant alterations of ABCB1 protein expression in the hematoencephalic barrier were noted during the studied periods. CONCLUSION: The administration of vildagliptin (5 mg/kg) to rabbits with alloxan-induced type 2 DM promotes the recovery of P-gp expression in the jejunum, liver, and kidney, which were reduced due to the underlying pathology. Meanwhile, its administration to healthy animals had no significant effect on the expression of P-gp.

17 March 2026 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
МММарина Майстренко
Марина Майстренко
EME.A. Maksimtseva
E.A. Maksimtseva
ONOksana Nemyatykh
Oksana Nemyatykh
INI.A. Narkevich
I.A. Narkevich
MKMikhail Kupriyanov
Mikhail Kupriyanov
ETE.S. Terekhov
E.S. Terekhov
Objective. To assess the quality of life in pediatric patients after COVID-19. Material and methods. An observational multiple-center retrospective-prospective study included data on 107 pediatric quality of life questionnaires (QUALIN and PedsQL 4.0) and 80 pediatrician questionnaires. Statistical analysis of primary data was performed using Pandas (data preparation and processing), NumPy, SciPy, Matplotlib (statistical computing), and Seaborn (results visualization). Results. QoL scores decline after discharge in the following areas: behavior and communication (by 23.2%), ability to be alone (by 32.0%), and neuropsychic development and physical health (by 18.8%). Notably, physical functioning scores in children decreased by 20% in 2 years after discharge. The incidence of doctor visits after COVID-19 increased in cohorts of children under 1 year, 1—3 years, and 3—7 years. Consolidated QoL scores of parents showed steady increase over the study period that was generally consistent with data of QUALIN and PedsQL 4.0 questionnaires. QoL in patients with high adherence to treatment in post-hospital period was higher (p=0.0256) at the final stages of follow-up than in children who did not take the prescribed medications at discharge. Conclusion. There is decline in QoL in children in post-hospital treatment of COVID-19. The effeciveness of QoL recovery is associated with adherence to treatment after discharge.